Home Health & Hospice Week
APRIA LOWERS EARNINGS PROJECTIONS
A variety of factors are hitting Apria Healthcare Group Inc. hard.
Slow-downs in Apria's durable medical equipment, respiratory medication and infusion therapy business lines have caused the Lake Forest, CA-based company to cut its earnings forecast for the year.
The news that Apria expects full year revenue growth from 2 percent to 3 percent instead of 5 percent to 6 percent sent the company's stock down 17 percent to a two-year low, although the stock price has since rebounded somewhat, press reports note. At press time Apria's stock was trading at about $24.50.
Increases in fuel and health benefit costs, hurricane-related expenses and decreases in the average sales prices (ASPs) for Medicare-reimbursed respiratory drugs also contributed to the decline, Apria says in a release.
Analysts warn of further bad news for both Apria and competitor Lincare Inc. if Medicare reduces the inhalation drug dispensing fee as threatened (see Eli's HCW, Vol. XIV, No. 36). The same goes for smaller, privately-owned inhalation drug providers.
Good news: Analyst Balaji Gandhi of Pacific Growth Equities in San Francisco says Apria's revenue slowdown does not appear to be an industry-wide problem, the Los Angeles Times reports. "Many of the smaller players ... continue to grow and do well," Gandhi told the paper.
Lawsuit settled: Apria also finalized its $17.6 million settlement of a whistleblower suit and saw another qui tam suit dismissed, the company says.
CFO Amin Khalifa declined to comment on whether Apria has found a buyer, after putting itself up for sale this summer, the Times says.
Wachovia analyst William Bonello isn't counting on the company finding a suitor, according to TheStreet.com. When Apria stock was trading at about $35, Bonello said "we think it is unlikely that a financial or strategic buyer will pay even the current price, given the low growth and limited free cash flow available to cover the cost of debt."
Home Health & Hospice Week
- Therapy:
OIG HITS THERAPY HOT BUTTON IN NEWEST AUDIT
Medical reviewers deny therapy visits on new grounds.
A new federal report on home health agency [...] - Medical Review:
HOLD ONTO YOUR THERAPY DOLLARS WITH THESE 6 STEPS
A pre-billing audit is key to accurate therapy claims.
In the wake of the feds' intense [...] - Legislation:
BUDGET AX HANGS OVER HOME CARE PROVIDERS' NECKS
Freeze on inflation update threatened.
Members of Congress searching for budget cuts in the wake of [...] - Finance:
APRIA LOWERS EARNINGS PROJECTIONS
Fuel costs, hurricane expenses and ASP declines contribute to woes.
A variety of factors are hitting [...] - Reimbursement:
DEFERRED COMP DECISION COSTS HHA $17K
Neither a borrower nor a lender be, PRRB decision suggests.
Even if the feds give a [...] - Compliance:
STOP DME WHISTLEBLOWERS BEFORE THEY STOP YOU
With qui tam suits breaking out all over, now is the time for a compliance [...] - Industry Notes:
INTERMEDIARY CRACKS DOWN ON DRESSINGS DIAGNOSIS CODE
Will your V58.3 claims measure up?
Get ready for increased scrutiny for claims with V58.3 as [...]
